

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PW MEDTECH GROUP LIMITED

普 华 和 顺 集 团 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

VOLUNTARY ANNOUNCEMENT

BOARD AUTHORISATION FOR EXERCISE OF THE REPURCHASE MANDATE

Reference is made to the general mandate granted to the board of directors (the “**Board**”) of PW Medtech Group Limited (the “**Company**”) to repurchase shares of the Company (the “**Shares**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) of not exceeding 10% of the total number of Shares in issue as at the date of the annual general meeting of the Company held on 28 May 2014 (i.e. up to 167,205,491 Shares) (the “**Repurchase Mandate**”). The Repurchase Mandate will lapse at the conclusion of the next annual general meeting or the revocation or variation of such mandate by the shareholders of the Company in a general meeting.

The Company is pleased to announce that at a Board meeting of the Company held on 2 December 2014, the Board has authorised to utilize a sum up to HK\$100,000,000 to conduct on-market repurchases pursuant to the Repurchase Mandate. The timing, price and amount of repurchases will be determined based upon market conditions and other factors. The Company believes that such repurchases will be in the best interest of the Company and its shareholders.

The Company will make repurchases pursuant to the Repurchase Mandate in accordance with the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) and the applicable laws of Hong Kong.

As at the date of this announcement, so far as the Company is aware after making all reasonable enquiries, none of the core connected persons (as defined in the Listing Rules) of the Company has indicated any present intention to sell any Shares to the Company.

Shareholders of the Company and potential investors should note that the exercise of the Repurchase Mandate by the Company will be subject to market conditions and will be at the absolute discretion of the Board. There is no assurance of the timing, quantity or price of any repurchases. Shareholders of the Company and potential investors should exercise caution when dealing in the Shares.

By Order of the Board
PW Medtech Group Limited
LIN Junshan
Chairman

Hong Kong, 2 December 2014

As at the date of this announcement, the Board comprises one executive director, namely, Mr. JIANG Liwei; three non-executive directors, namely, Mr. LIN Junshan, Ms. Yue'e ZHANG and Mr. FENG Dai; and three independent non-executive directors, namely, Mr. ZHANG Xingdong, Mr. CHEN Geng and Mr. WANG Xiaogang.